KCA
Search
- Page Path
- HOME > Search
Original Article
- Gastrointestinal cancer
- ALYREF-Mediated Regulation of TBL1XR1 and KMT2E Synergistically Upregulates APOC1, Contributing to Oxaliplatin Resistance in Esophageal Cancer
- Jie Hu, Qilong Liu, Bi Feng, Yanling Lu, Kai Chen
- Cancer Res Treat. 2025;57(4):1064-1089. Published online February 4, 2025
- DOI: https://doi.org/10.4143/crt.2024.1091
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
Esophageal cancer (EC) is a rapidly progressing malignancy characterized by a low survival rate and limited treatment success, largely due to late-stage detection, frequent recurrence, and a high propensity for metastasis, despite ongoing advances in therapeutic strategies. While oxaliplatin (L-OHP) is a potent chemotherapeutic agent that induces apoptosis in EC cells, its effectiveness is significantly hindered by the development of resistance.
Materials and Methods
The assessment of gene and protein expression was conducted through a combination of quantitative real-time polymerase chain reaction, Western blot, and immunohistochemical staining. Cell viability was assessed using the cell counting kit-8 assay. The interactions among ALYREF, TBL1XR1, KMT2E, and APOC1 were investigated through RNA immunoprecipitation, chromatin immunoprecipitation (ChIP), ChIP-reChIP, RNA pulldown, and dual-luciferase assays. An in vivo mouse model of EC was established.
Results
Expression levels of both APOC1 and ALYREF were elevated in L-OHP–resistant EC tissues and cell lines, and their silencing enhanced sensitivity to L-OHP. TBL1XR1 and KMT2E synergistically upregulated APOC1 expression. Moreover, ALYREF recognized the 5-methylcytosine (m5C) sites on TBL1XR1 and KMT2E mRNAs, stabilizing these transcripts and promoting APOC1 expression. The regulatory role of these interactions was further validated in vivo.
Conclusion
This study demonstrated that ALYREF interacted with the m5C sites on TBL1XR1 and KMT2E mRNAs, enhancing their stability and leading to increased transcription of APOC1, which in turn contributed to L-OHP resistance in EC. These findings suggest that targeting APOC1 could be a promising strategy for overcoming L-OHP resistance in EC. -
Citations
Citations to this article as recorded by
- RNA Regulatory Networks: Key Hubs in the Panorama of Cancer and Emerging Therapeutic Targets
Xuan Yin, Zengkan Du, Shuya Jiang, Yan Liao, Changli Wang, Jiaqi Li, Haoling Zhang, Ting‐Ting Wei, Wangzheqi Zhang, Zui Zou
MedComm.2026;[Epub] CrossRef - m5C RNA modification in gastrointestinal cancers: a comprehensive review from molecular mechanism to clinical implication
Chao Xu, Qinwen Ye, Hao Wang, Yue Yu
Biology Direct.2026;[Epub] CrossRef - Aly as a Key Regulator of DNA Repair and Immune Evasion in Esophageal Squamous Cell Carcinoma Radioresistance
Shizhen Ding, Huichao Liang, Jianlin Wang, Hong Zhu, Xiaofang Li, Qiu Zong, Xueqing Ma, Xujing Lu, Zhiqiang Sun, Wei Li, Judong Luo
International Journal of Radiation Oncology*Biology*Physics.2026;[Epub] CrossRef - Targeting KIF18B overcomes oxaliplatin resistance in esophageal squamous cell carcinoma via suppression of the ATR/CHK1 axis
Wei Liu, Qianru Wang, Xiao Tan, Chunyu Cao, Bole Tian
Molecular Genetics and Genomics.2026;[Epub] CrossRef - RNA m5C methylation in cancer: mechanisms and biological impact
Zhenyu Guan, Wendong Li, Yuting He, Wenzhi Guo
Oncogenesis.2025;[Epub] CrossRef
- RNA Regulatory Networks: Key Hubs in the Panorama of Cancer and Emerging Therapeutic Targets
- 4,045 View
- 129 Download
- 5 Web of Science
- 5 Crossref
First
Prev
